Novo Nordisk Shares Face Mounting Headwinds

The investment case for pharmaceutical giant Novo Nordisk is encountering significant pressure. A combination of revised analyst outlooks, emerging legal challenges in the United States, and intensifying competition is weighing on the stock, which continues its recent downward trajectory.

Legal and Competitive Pressures Intensify

A new layer of uncertainty has been introduced by a recently filed class-action lawsuit in the US targeting Ozempic and other GLP-1 drugs. While such litigation is not uncommon in the pharmaceutical sector, its timing adds to the current negative sentiment surrounding the company.

Compounding these challenges is the formidable progress of direct competitor Eli Lilly in the lucrative weight-loss drug market. Industry observers currently place Eli Lilly in a leading position, a dynamic that increases the urgency for Novo Nordisk to demonstrate tangible progress from its own development pipeline.

Diverging Views from Market Experts

Recent analyst commentary highlights a split in market sentiment. On Tuesday, two major investment banks released updated assessments with notably different conclusions.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Kepler Cheuvreux made a substantial reduction to its price target, cutting it from 510 to 430 Danish kroner. The firm cited more cautious expectations for 2026 and the recent flow of negative news as key reasons. Despite this downward revision, the analyst team maintained its “Buy” rating, pinning hopes on the potential US launch of an oral Semaglutide formulation to reverse the prevailing negative momentum.

In contrast, JPMorgan reaffirmed its “Overweight” recommendation and a 350 Danish kroner price target. Its analysts present a longer-term view, acknowledging that price reductions for GLP-1 weight-loss medications are pressuring revenue per unit. Their thesis, however, is that these lower prices will ultimately stimulate higher sales volumes, though they concede this volume-driven effect will require time and investor patience to materialize.

The Path Forward

The market is now awaiting concrete signs of a turnaround. Upcoming product launches and pipeline updates scheduled for early 2026 are viewed as critical near-term catalysts. These events are expected to provide clarity on whether the current share price levels represent a strategic opportunity or merely a pause in a broader declining trend. For now, the stock remains firmly on the defensive.